Vendor, Schenectady, NY
Institute for Clinical Pharmacodynamics, Inc.
UEI Z82HHPY83MC7, CAGE 6Y2X5
5 awards and $684,633 obligated between July 10, 2024 and September 25, 2026, 60% under full and open competition, against 16.2 offers on average where reported. 3 of the awards trace back to a SAM.gov solicitation on this site.
Sells to
Awarding agencies by dollars.
| Food and Drug Administration | $573,553 |
| National Institutes of Health | $111,080 |
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 3 |
| Competed Under SAP | 2 |
| Definitive Contract | 3 |
| Delivery Order | 1 |
Hear when Institute for Clinical Pharmacodynamics, Inc. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Institute for Clinical Pharmacodynamics, Inc. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $325,000
- Soonest
- July 31, 2027
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in biotechnology (except nanobiotechnology) to Food and Drug Administration, by dollars.
| President and Fellows of Harvard CollegeCambridge, MA | $10,869,531 |
| Dna Hive LLCRockville, MD | $7,461,715 |
| Tranquil Clinical and Research Consulting Services LLCWebster, TX | $4,117,132 |
| The Research Foundation for the State University of New YorkBinghamton, NY | $3,684,500 |
| Aptargroup Inc.Congers, NY | $2,958,579 |
| The Critical Path InstituteTucson, AZ | $2,672,572 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75F40126C00025Definitive Contract, June 30, 2026, Competed Under SAP, 1 offers | FDA Office of Acq Grant SVCSFood and Drug Administration | BAA Contract - Development of Susceptibility Guidance for Daptomycin and Enterococcus Species Using Pharmacometric ApproachesNAICS 541715, PSC B529 | $325,000 |
| 75F40124C00080Definitive Contract, August 19, 2024, Competed Under SAP, 1 offersSolicitation | FDA Office of Acq Grant SVCSFood and Drug Administration | Fdabaa-24-00123: Development of Modernized Susceptibility Guidance for Nitrofurantoin Dosing Using a Dynamic Urinary Tract in Vitro InfectioNAICS 541714, PSC B529 | $248,553 |
| 75N93026F00001Delivery Order, September 25, 2026, Full and Open Competition, 2 offers | National Institutes of Health NiaidNational Institutes of Health | C02 - PK-PD Analysis of Mouse Model Efficacy and PK Data for Antibacterial CompoundsNAICS 541714, PSC AN11 | $111,080 |
| 75F40123C00140Definitive Contract, August 5, 2024, Full and Open Competition, 1 offers | FDA Office of Acq Grant SVCSFood and Drug Administration | No Cost Modification to Change the Period of Performance End Date to March 29, 2025.NAICS 541714, PSC B529 | $0 |
| 75N93024D00013July 10, 2024, Full and Open Competition, 76 offersSolicitation | National Institutes of Health NiaidNational Institutes of Health | Pre-Clinical Models of Infectious Diseases - Task Area CNAICS 541714, PSC AN11 | $0 |
- Places of performance
- New York
- Product and service codes
- B529 Scientific Data StudiesAN11 Health R&D Services; Health Care Services; Basic Research
- Transactions
- 9 across 5 awards